In March 2020, Hannu Rajaniemi pivoted his biotech company Helix Nanotechnologies’ focus from cancer therapies to Covid-19 vaccines.
The role biotech start-ups can play in a pandemic
Rajaniemi originally co-founded Helix Nanotechnologies in Cambridge, Massachusetts in 2013 to develop cancer therapeutics, which was a personal mission: His mother got sick with and eventually passed due to metastatic breast cancer.
When the company pivoted to working on Covid-19 vaccines, he knew his start-up wouldn’t be one of the first vaccines out of the gate.
“That would have required billions in [Operation] Warp Speed funding,” Rajaniemi says. (HelixNano has received $6.4 million in total funding as of May, according to Crunchbase, from investors including Y Combinator, and has received grant money from Google billionaire Eric Schmidt’s Schmidt Futures.
“In this crisis, the role of a start-up is to pursue more technically challenging, second-generation approaches and find solutions that the less agile bigger players might miss,” he says.
While the first wave of Covid vaccines distributed in the United states from Pfizer/BioNTech, Moderna and Johnson & Johnson have to adapt their vaccines to new strains, HelixNano’s booster vaccine is designed to “provide much broader immunity,” he says.
“The reason we got into this … was that we were worried about mutated SARS-CoV-2 strains able to evade vaccine immunity,” Rajaniemi says. “That is exactly the scenario that is now playing out with the South African, Brazilian and other emerging variants.”
New vaccine technologies: Essentially ‘a zoom function and an amplify function’
Developing a vaccine that is resistant to virus mutations is “an extremely challenging problem technically,” Rajaniemi says.
But with the advantage of being able to build on all the knowledge scientists now have about the virus, HelixNano invented “two completely new vaccine technologies” for which they’ve filed for patents, according to Rajaniemi.
“Essentially, we have a ‘zoom’ function and an ‘amplify’ function for mRNA vaccines,” he says. (Both the Pfizer-BioNTech and Moderna vaccines are mRNA technology, as is Helix Nanotechnologies’ booster.)
“We can make vaccines both more targeted and more powerful than was previously possible,” says Rajaniemi.
The first technology Helix Nanotechnologies developed makes vaccines more accurate.
“Traditional vaccines are blunt instruments. You show the immune system a bit of the virus — like the spike protein that SARS-CoV-2 uses to infect cells — and [the body] generates antibodies against it,” Rajaniemi says. And “those antibodies are essentially random.”
However, HelixNano’s new technology directs antibodies at a very specific part of the virus’ spike protein that “matters the most for preventing infection,” according to Rajaniemi.
“To use a nerdy analogy, imagine the virus is the Death Star [space station from Star Wars]. To blow it up you need to hit a very small target — the thermal exhaust port,” says Rajaniemi (who is also a published science fiction author).
“Your X-Wings [starfighters] could just randomly fire at the whole Death Star, but you would have to get very, very lucky to destroy it,” he says.
“But if you concentrate all your fire on the exhaust port, you have a much better chance — even if your shots get less accurate as the virus mutates.”
The second vaccine technology HelixNano developed is a way to multiply the body’s immune response to a specific vaccine target by a factor of 100.
Taken together, these two technological advances are what HelixNano has used to build their Covid-19 mutation-resistant booster vaccine.
Beyond its own vaccine technology innovations, HelixNano is also collaborating with Louis Falo’s lab at University of Pittsburgh to make a vaccine technology that can be applied to the skin, rather than by a shot, which therefore can be self-administered.
“The mRNA platform has proven to be effective for vaccination, but does have limitations including the requirement for very low temperatures (cold-chain) across the storage, delivery, and deployment process,” says Falo, who is chairman of the dermatology department at the University of Pittsburgh and a bioengineering professor.
“We imagine an mRNA vaccine that is stable at room temperature and can therefore be readily deployed in global vaccination campaigns the same way that one would distribute and apply Band-Aids.”
(Separately, Falo’s lab has its own skin application vaccine called PittCoVacc, which has submitted preclinical data to the Food and Drug Administration as a Pre-Investigational New Drug Application application.)
Image Credit: CNBC
Experts have discovered what they believe is the world’s most mutated COVID strain – and there’s one detail in particular that has scientists worried. Scientists have detected what is believed to be the world’s [...]
SARS-CoV-2, the virus that causes COVID-19, likely does not directly infect the brain but can still inflict significant neurological damage, according to a new study from neuropathologists, neurologists, and neuroradiologists at Columbia University Vagelos [...]
ANSTO has contributed to a comprehensive investigation of a promising type of nanoparticle that could potentially be used for intractable brain cancers in a combined therapy. The study, which was led by Dr. Moeava [...]
The immune response needed to protect people against reinfection with the coronavirus will be explored in a new human challenge trial, researchers have revealed. Human challenge trials involve deliberately exposing healthy people to a [...]
Researchers from Duke University are developing a flu shot with the new technology that was used for two coronavirus vaccines. Both the Pfizer-BioNTech and the Moderna shots use part of the virus's genetic code [...]
Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19. In a paper published in the journal Nanoscale, [...]
Researchers have developed a new superbug-destroying coating that could be used on wound dressings and implants to prevent and treat potentially deadly bacterial and fungal infections. The material is one of the thinnest antimicrobial [...]
The U.S. is recommending a "pause" in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots. In a joint statement Tuesday, the Centers for Disease Control [...]
The South African coronavirus variant is better at "breaking through" the defences of the Pfizer/BioNTech vaccine than other forms of the virus, Israeli experts said Sunday. However, one of the authors told AFP that [...]
EPFL scientists have developed AI-powered nanosensors that let researchers track various kinds of biological molecules without disturbing them. The tiny world of biomolecules is rich in fascinating interactions between a plethora of different agents [...]
A team of researchers from the Institute for Infectious Diseases (IFIK) at the University of Bern and the Federal Institute of Virology and Immunology (IVI) have assessed virus growth and activation of the cellular [...]
Researchers at Brown University have succeeded in creating the first wireless, implantable, rechargeable, long-term brain-computer interface. The wireless BCIs have been implanted in pigs and monkeys for over 13 months without issue, and human [...]
The coronavirus outbreak made household names of companies like Moderna Inc. and BioNTech SE, whose shots offered hope for ending the pandemic. Now a new wave of vaccines is on the horizon that may get the [...]
Researchers at the University of Southampton have developed a new way of using nanomaterials to identify and enrich skeletal stem cells—a discovery which could eventually lead to new treatments for major bone fractures and [...]
In March 2020, Hannu Rajaniemi pivoted his biotech company Helix Nanotechnologies' focus from cancer therapies to Covid-19 vaccines. The role biotech start-ups can play in a pandemic Rajaniemi originally co-founded Helix Nanotechnologies in Cambridge, Massachusetts in [...]
The rapid mass testing strategy costing just £1 a day per child can get children back to school and economies up and running, according to experts. That is the small price of the [...]